(Q40447501)

English

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. (English)

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

phase III clinical trial

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Gerd-Rüdiger Burmester

1

object named as

Gerd R Burmester

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

author name string

Yong Lin

2

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Rahul Patel

3

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Janet van Adelsberg

4

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Erin K Mangan

5

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Neil M H Graham

6

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Hubert van Hoogstraten

7

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Deborah Bauer

8

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Juan Ignacio Vargas

9

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Eun Bong Lee

10

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

language of work or name

0 references

publication date

17 November 2016

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

76

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

840-847

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Biologic monotherapy in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Evolution of treatment for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

The role of interleukin 6 in the pathophysiology of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Hepatoprotection via the IL-6/Stat3 pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

22 September 2017

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

15 June 2018

Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

20 August 2018

Serum Interleukin-6 Level is a Sensitive Parameter of Disease Activity in Rheumatoid Arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

20 August 2018

Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

20 August 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5530335

20 August 2018

Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine production by synovial T cells in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27856432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2016-210310

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40447501&oldid=1493958438"